David Guay
Vice President, Innovation & Technology Feldan Therapeutics
David Guay is the Research Director at Feldan Therapeutics since 2009. Dr. Guay received his PhD in molecular and cell biology from Laval University for its research on the implication of a transcription factor in DNA repair and chemotherapy resistance mechanisms. He holds a postdoctoral fellowship in chemical engineering from McGill University where he developed a DNA delivery technique based on a non-thermal plasma technology. His research at Feldan Therapeutics focuses on the “Feldan Shuttle”, a peptide-based technology designed to deliver native proteins, namely transcription factors, antibodies and CRISPR nucleases, in therapeutic cells.
Seminars
Wednesday 2nd December 2026
Expanding Targeted Delivery Beyond the Liver: Harnessing Peptides to Unlock the Next Generation of Oligonucleotide Therapeutics
1:30 pm
- Explore how peptide-based delivery technologies are enabling targeted delivery of antisense oligonucleotides (ASOs) to extrahepatic tissues, including the lung and oncology indications.
- Discover strategies for overcoming tissue-specific delivery barriers to improve cellular uptake, therapeutic efficacy, and target engagement.
- Examine case studies demonstrating how peptide conjugates are expanding the clinical potential of oligonucleotide therapeutics across previously inaccessible disease areas.
